Yoshihiko Hatanaka - Astellas Pharma CEO and President and Representative Director
| ALPMY Stock | USD 9.47 0.02 0.21% |
CEO
Mr. Yoshihiko Hatanaka was serving as Chairman of the Board, Chairman of the Board of Directors and Representative Director in Astellas Pharma Inc. since April 1, 2018. His previous titles include President, Director of Business Planning in Main Business Strategy Unit, Executive Officer and Senior Executive Officer in the Company. He previously served as President and Chief Executive Officer in two USbased subsidiaries. He used to work for Fujisawa Pharmaceutical Co., Ltd. He obtained his bachelor degree in Economics from Hitotsubashi University in May 1980. since 2018.
| Age | 61 |
| Tenure | 6 years |
| Phone | 81 3 3244 3000 |
| Web | https://www.astellas.com |
Astellas Pharma Management Efficiency
The company has return on total asset (ROA) of 0.0653 % which means that it generated a profit of $0.0653 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0898 %, meaning that it generated $0.0898 on every $100 dollars invested by stockholders. Astellas Pharma's management efficiency ratios could be used to measure how well Astellas Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | CEO Age | ||
| Emma Walmsley | GlaxoSmithKline PLC ADR | 55 | |
| Javier Ribes | Grifols SA ADR | N/A | |
| Joseph Jimenez | Novartis AG ADR | 58 | |
| Severin Schwan | Roche Holding Ltd | 56 | |
| Andrew Witty | GlaxoSmithKline PLC ADR | 50 | |
| Brian McNamara | GlaxoSmithKline PLC ADR | 49 | |
| Richard Saynor | Novartis AG ADR | 57 | |
| Paul Hudson | Novartis AG ADR | 51 | |
| Bruno Strigini | Novartis AG ADR | N/A | |
| Osamu Nagayama | Roche Holding Ltd | 69 | |
| Elizabeth Barrett | Novartis AG ADR | 56 | |
| Nacho Abia | Grifols SA ADR | 56 | |
| Pascal Soriot | AstraZeneca PLC ADR | 60 | |
| PerOlof Attinger | Roche Holding Ltd | 58 | |
| Olivier Brandicourt | Sanofi ADR | 62 | |
| Francesco Balestrieri | Novartis AG ADR | N/A | |
| Michael Ball | Novartis AG ADR | 62 | |
| Victor Deu | Grifols SA ADR | N/A | |
| Deborah Waterhouse | GlaxoSmithKline PLC ADR | N/A | |
| Chris Ilsley | Novartis AG ADR | N/A | |
| Albert Roura | Grifols SA ADR | N/A | |
Management Performance
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 |
Astellas Pharma Leadership Team
Elected by the shareholders, the Astellas Pharma's board of directors comprises two types of representatives: Astellas Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Astellas. The board's role is to monitor Astellas Pharma's management team and ensure that shareholders' interests are well served. Astellas Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Astellas Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yukihiko Sato, President of Sales and Marleting, Sr. Corporate Executive and Sr. VP | ||
| Naoki BSc, Chief VP | ||
| Shiro Yamamoto, Executive Officer, Manager of Tokyo Office in Main Sales Unit | ||
| Yutaka Kase, Independent Director | ||
| Hironobu Yasuda, Independent Director | ||
| Naoki Okamura, Executive Officer, Director of Business Planning | ||
| Yoshihiko Hatanaka, CEO and President and Representative Director | ||
| Eisuke Nozawa, Executive Officer, Director of Pharmaceutical Affairs | ||
| Nate Crisel, Vice President - Real World Informatics & Analytics | ||
| Hideki Shima, Executive Officer, Director of Technology Planning in Main Pharmaceutical Technology Unit | ||
| Akihiko Iwai, Executive Officer, Director of Research Portfolio & Science in Main Research Unit | ||
| Linda Friedman, General Counsel | ||
| Taiji Sawamoto, Executive Officer, Director of Clinical Pharmacology in Main Development Unit | ||
| Yukio Matsui, Executive Officer, Manager of Global Marketing Strategic Function | ||
| Yasumasa Masuda, CFO, Sr. VP and Sr. Corporate Executive | ||
| Yuichi Murakami, Director of Accounting | ||
| Akira Kamimura, Director of Accounting | ||
| Masatoshi Kuroda, Executive Officer and Presidentident of Subsidiary | ||
| Nobue Yasuda, Gen Department | ||
| Fumiaki Sakurai, Executive Officer, Director of Human Resources | ||
| Mamoru Sekiyama, Independent Director | ||
| Masaaki Hirano, Executive Officer, Director of Business Planning | ||
| Collette Taylor, VP HR | ||
| Minoru Kikuoka, CFO Officer | ||
| Noriyuki Uematsu, Independent Director | ||
| Takahisa Iizuka, Executive Officer, Director of Sales Promotion | ||
| Tomokazu Fujisawa, Director | ||
| Hiroo Sasaki, Independent Director | ||
| Yoshiro Miyokawa, Chief Admin. Officer, Chief Compliance Officer, Executive VP, Representative Director, Chairman of Global Compliance Committee and Member of Compensation Committee | ||
| Takuya Oshida, Executive Officer, Chief Director of Medical Affairs | ||
| Katsuyoshi Sugita, Chief Officer | ||
| Shigeki Tanaka, Executive Officer, Director of 1st Japan & Asia Clinical Development in Main Development Unit | ||
| Catherine Levitt, G Counsel | ||
| Atsushi Kamide, Executive Officer, Director of Product Management in Main Sales Unit | ||
| Kiyotaka Hayashi, Executive Officer, Manager of Kyushu Office in Main Sales Unit | ||
| Etsuko Okajima, Independent Director | ||
| Keiko Yamagami, Independent Director | ||
| Chikashi Takeda, Executive Officer, Director of Business Planning | ||
| Shoji Yokota, Executive Officer, Director of Technology Promotion in Main Technology Unit | ||
| Wataru Uchida, Executive Officer, Director of Pharmacology Research Institute in Main Research Unit | ||
| Nobuaki Tanaka, Executive Officer, Manager of Chiba Office in Main Sales Unit | ||
| Chihiro Yokota, Executive Officer, Director of Licensing and Alliance | ||
| Masao Yoshida, Senior Executive Officer and Presidentident and CEO of Subsidiaries | ||
| Katzumi Ozawa, Executive Officer, Manager of Tokyo Office in Main Sales Unit | ||
| Kazuhiro Sako, Executive Officer and Presidentident of Subsidiary | ||
| Hitoshi Kanamori, Independent Director | ||
| Stig Ogata, VP Communications | ||
| Bernhardt Zeiher, President - Development, Chief Medical Officer | ||
| Tadashi Hara, Executive Officer, Director of Sales Strategy in Main Sales Unit | ||
| Sef Kurstjens, Chief Medical Officer | ||
| Kenji Yasukawa, Senior Executive Officer, Manager of Vaccine Business Promotion Office | ||
| Mitsunori Matsuda, Sr. VP of Technology and Sr. Corporate Executive | ||
| Toru Yoshimitsu, Executive Officer, Director of Product Strategy | ||
| Kazunori Okimura, Executive Officer, Director of Legal Affairs & Compliance | ||
| Makoto Takeuchi, Executive Officer, Director of Research Promotion | ||
| Hiroko Sakai, Director | ||
| Masafumi Nogimori, Chairman of the Board, Representative Director | ||
| Yasuhiro Kanzaki, Executive Officer, Manager of Osaka Office in Main Sales Unit | ||
| Yoshiharu Aizawa, Independent Director | ||
| Yoshitsugu Shitaka, Executive Officer and Presidentident of Subsidiary |
Astellas Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Astellas Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 26.19 B | |||
| Shares Outstanding | 1.83 B | |||
| Shares Owned By Institutions | 0.03 % | |||
| Price To Earning | 25.98 X | |||
| Price To Book | 2.44 X | |||
| Price To Sales | 0.02 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Astellas Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Astellas Pharma's short interest history, or implied volatility extrapolated from Astellas Pharma options trading.
Pair Trading with Astellas Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Astellas Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Astellas Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Astellas Pink Sheet
| 0.83 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.67 | RHHBY | Roche Holding | PairCorr |
Moving against Astellas Pink Sheet
| 0.85 | CPNG | Coupang LLC Financial Report 14th of May 2024 | PairCorr |
| 0.68 | GERN | Geron Financial Report 9th of May 2024 | PairCorr |
| 0.67 | HAS | Hasbro Inc Upward Rally | PairCorr |
| 0.59 | META | Meta Platforms | PairCorr |
| 0.59 | PH | Parker Hannifin Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Astellas Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Astellas Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Astellas Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Astellas Pharma to buy it.
The correlation of Astellas Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Astellas Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Astellas Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Astellas Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Astellas Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Astellas Pink Sheet analysis
When running Astellas Pharma's price analysis, check to measure Astellas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astellas Pharma is operating at the current time. Most of Astellas Pharma's value examination focuses on studying past and present price action to predict the probability of Astellas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astellas Pharma's price. Additionally, you may evaluate how the addition of Astellas Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |